1. Introduction {#sec1}
===============

Osteoarthritis (OA) is one of the most prevalent causes of disability in the aging population and has enormous economic and social consequences. However, existing nonsurgical treatment options only provide symptomatic relief but have no effect on the progression of the disease. The lack of progress in the development of structural disease-modifying drugs for OA therapy is largely due to our limited understanding of the pathogenesis of OA and insufficient knowledge regarding the molecular targets or key OA disease genes for therapeutic intervention.

OA is not merely an articular cartilage disease, but a disease of the whole joint. An important local factor to the health of the knee joints is the structural integrity and biochemical properties of the knee meniscus. Knee meniscus is a specialized tissue that plays a vital role in load transmission, shock absorption, and joint stability. In recent years there has been a dramatic advance in our understanding of the integral role of the meniscus for the knee functions and the consequences of meniscal abnormality in cartilage degeneration. Studies found that meniscal degeneration is a general feature of OA \[[@B1], [@B2]\]; meniscal lesions at baseline were more common in the knees that developed OA than in the knees that did not develop OA \[[@B3]\] and that OA meniscal cells displayed a distinct gene expression profile different from normal meniscal cells \[[@B4]\]. These findings indicate that meniscal changes or abnormalities are involved in the OA disease process. The involvement of meniscal changes or abnormalities in the OA disease process has also been highlighted by recent findings that meniscal extrusion, vascular penetration (angiogenesis), and calcification are associated with cartilage degeneration and subchondral lesions in OA \[[@B5]--[@B7]\]. Meniscal abnormalities such as meniscal degeneration, inflammation, and angiogenesis may represent as new targets for the development of disease-modifying drugs for OA therapy, especially for a subgroup of OA patients who develop severe meniscal lesions before developing severe cartilage degeneration \[[@B8], [@B9]\].

Phosphocitrate (PC), a potent calcification inhibitor, is a naturally occurring compound originally identified in rat liver mitochondrial extract \[[@B10], [@B11]\]. PC prevented soft tissue calcification and inhibited calcium crystal-induced mitogenesis, crystal-induced expression of matrix metalloproteinases (MMPs), and crystal-induced cell death \[[@B12]--[@B15]\]. In Hartley guinea pig model of crystal-associated OA, PC inhibited meniscal calcification and reduced the severity of cartilage degeneration \[[@B16]\]. These findings provide support for the notion that calcification inhibitors are potentially disease modifying drugs for crystal-associated OA therapy. It is believed that PC exerts its disease modifying activity by inhibiting the formation of articular calcium crystals and the detrimental interaction between the crystals and cells \[[@B17]\]. However, two studies found that bisphosphonates, which are also potent calcification inhibitors, failed to inhibit cartilage degeneration in animal models of OA, including the Hartley guinea pig model of crystal-associated OA \[[@B18], [@B19]\], raising doubts as to whether calcification inhibitors are potentially disease-modifying drugs for OA therapy. An alternative mechanism underlying the disease modifying activity of PC may be present.

We previously reported that PC downregulated the expression of many genes classified in inflammatory response and angiogenesis in OA fibroblast-like synoviocytes (FLSs) and OA meniscal cells in the absence of calcium crystals \[[@B20], [@B21]\]. These findings suggest that the molecular mechanism underlying the disease-modifying activity of PC is more complicated than originally thought. In this study, we sought to further investigate the gene expression-modulating activity of PC and determine the expressions of select PC-targeted genes in menisci derived from OA patients. The hypothesis to be tested is that PC exerts its disease modifying activity, at least in part, by modulating the abnormal expressions of genes involved in the OA disease process. The information gained is not only important for a better understanding of the molecular mechanisms underlying the disease modifying activity of PC but may also valuable for the identification of disease candidate genes involved in the OA disease process.

2. Materials and Methods {#sec2}
========================

2.1. Materials {#sec2.1}
--------------

Dulbecco\'s modified eagle medium (DMEM), fetal bovine serum (FBS), stock antibiotic/antimycotic mixture are products of Invitrogen (Carlsbad, CA, USA). Superfrost-Plus microscope slides and neutral buffered formalin (10%) were obtained from Allegiance Inc. (McGaw Park, IL, USA). PC was prepared as described \[[@B22]\]. Antibodies specific to Fc fragment of IgG, low affinity IIIb receptor (FCGR3B), SRY (sex determining region Y)-box 9 (Sox-9), and fibroblast growth factor receptor 3 (FGFR-3) were obtained from Santa Cruz Biotechnology (Dallas, TX, USA). Antibody specific to leukocyte immunoglobulin-like receptor, subfamily B member 3 (LILRB3) was obtained from Lifespan Biosciences (Seattle, WA, USA).

2.2. Meniscal Explant Culture and RNA Extraction {#sec2.2}
------------------------------------------------

OA meniscal tissue specimens were minced into small pieces and cultured in a six well-cluster plate (350 mg per well) at 37°C in DMEM containing 1% FBS and 0.5% antibiotic/antimycotic solution. Twenty-four hours later, the medium in the top three wells was replaced with DMEM containing 1% FBS and 1 mM of PC and the medium in the bottom three wells was replaced with DMEM containing 1% FBS without PC as control. Every three days, the medium was changed. On the eighth day, the medium was changed again. Twenty-four hours later, the meniscal explants were collected, snap-freezed, and stored in −70°C freezer until use. Total RNA was extracted from these snap-freezed meniscal explants using Trizol reagent (Invitrogen, Carlsbad, CA, USA) and purified using Oligotex kit (Qiagen, Valencia, CA, USA). These RNA samples were used for microarray analysis.

Meniscal tissue specimens were collected with the approval of the authors\' Institutional Review Board from end-stage OA patients undergoing knee joint replacement surgery and osteosarcoma patients undergoing lower limb amputation surgery at Carolinas Medical Center. The need for informed consent was waived because these meniscal specimens were surgical waste and no private patient information was collected. Meniscal specimens were collected in sterilized containers filled with tissue culture medium and transported to the laboratory from operating room using an ice box.

2.3. Microarray {#sec2.3}
---------------

RNA samples extracted from two independent experiments were used for microarray analysis. Briefly, double stranded DNA was synthesized using SuperScript double stranded cDNA synthesis kit using these RNA samples (Invitrogen, San Diego, CA, USA). The DNA product was purified using GeneChip sample cleanup module (Affymetrix, Santa Clara, CA, USA). cRNA was synthesized and biotin labeled using BioArray high yield RNA transcript labeling kit (Enzo Life Sciences, Farmingdale, NY, USA). The cRNA product was purified using GeneChip sample cleanup module and subsequently chemically fragmented. The fragmented and biotinylated cRNA was hybridized to HG-U133_Plus_2 gene chip using Affymetrix Fluidics Station 400 (Affymetrix, Santa Clara, CA, USA). The fluorescent signal was quantified during two scans by Agilent Gene Array Scanner G2500A (Agilent Technologies, Palo Alto, CA) and GeneChip operating Software (Affymetrix, Santa Clara, CA, USA). Genesifter software (VizX Labs, Seattle, WA, USA) was used for the analysis of differential gene expression and gene ontology.

2.4. Real-Time RT-PCR {#sec2.4}
---------------------

Briefly, cDNA was synthesized using TaqMan Reverse Transcription Reagents (Applied Biosystems, University Park, IL, USA) using the RNA samples described. Quantification of relative transcript levels for selected genes and the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was performed using ABI7000 Real Time PCR system (Applied Biosystems, University Park, IL, USA). TaqMan Gene Expression assay (Applied Biosystems, University Park, IL, USA) was used. CDNA samples were amplified with an initial Taq DNA polymerase activation step at 95°C for 10 minutes, followed by 40 cycles of denaturation at 95°C for 15 seconds and annealing at 60°C for one minute. Fold change was calculated and the expression level of the genes to be examined was normalized to the expression level of GAPDH. RT-PCR experiment was performed in triplicates using the same RNA sample for the microarray analysis.

2.5. Immunohistochemistry {#sec2.5}
-------------------------

Medial meniscal specimens derived from 6 end-stage OA patients and 3 osteosarcoma patients were used for examination. These meniscal specimens were fixed in 10% neutral buffered formalin for twenty-four hours and transferred to 70% ethyl alcohol. A portion of 5 mm wide specimen was transversely excised from the middle part of meniscus, embedded in Paraplast Plus paraffin, and sectioned with a Leica RM2025 microtome (Nussloch, Germany) to obtain 4 *μ*m serial transverse sections \[[@B23]\]. Sections were examined with immunohistochemical staining using specific antibodies. Briefly, paraffin-embedded sections were deparaffinized with xylene and rehydrated with graded ethanol. Endogenous peroxidase activity was blocked by incubation of the sections with freshly prepared 3% H~2~O~2~ in deionized water for 5 minutes at room temperature. Nonspecific binding was blocked by incubation of the sections with 100 *μ*L of 10% normal horse serum diluted in base solution (4% BSA and 5% nonfat dry milk in PBS) for 20 minutes. These sections were incubatedwith a specific primary antibody (2 *μ*g/mL) for 1 hour, followed with the secondary reagent specific for each antibody for 30 minutes (Immpress reagent kit, Vector, Inc., Burlingame, CA). Negative control was performed using mouse IgG to replace the primary specific antibody. Slides were rinsed in phosphate buffered saline three times and visualized using 3,3′-diaminobenzidine for 5 minutes. Slides were then counterstained with light green, dehydrated, and mounted with resinous mounting media. These immunostainings were graded on a scale of 0--3, where 0 = very weak staining; 1 = weak staining; 2 = moderate staining; 3 = strong staining.

2.6. Statistical Analysis {#sec2.6}
-------------------------

The difference between the immunostaining grades of the OA meniscal group and control group was analyzed using the Wilcoxon rank-sum test. *P* values less than 0.05 were considered significant. Statistical analysis was performed using the statistical analysis tool in the Sigma Plot software, version 12 (Systat software Inc., San Jose, CA).

3. Results {#sec3}
==========

3.1. Effect of PC on Gene Expressions {#sec3.1}
-------------------------------------

Microarrayanalysis revealed that of the more than 50,000 transcripts examined, 2561 transcripts displayed significant differential expressions (more than 2.0 fold) in PC-treated OA meniscal explants via untreated OA meniscal explants. A total of 1430 transcripts displayed decreased expressions and 1131 transcripts displayed increased expressions. The genes that fell into specific biological processes previously implicated in OA or suspected to have a role in OA are listed in Tables [1](#tab1){ref-type="table"}, [2](#tab2){ref-type="table"}, and [3](#tab3){ref-type="table"}.

As shown in [Table 1](#tab1){ref-type="table"}, the expressions of numerous genes classified in the immune response were downregulated by PC. Of the 120 differentially-expressed genes classified in the immune response, the expressions of 106 genes, including many genes encoding chemokines and cytokines, such as chemokine (C-C motif) ligand 20 (CCL20, −103.53 fold change), chemokine (C-C motif) ligand 5 (CCL5, −3.54 fold change), chemokine (C-C motif) receptor 5 (CCR5, −2.03 fold change), chemokine (C-X-C motif) ligand 3 (CXCL3, −10.03 fold), interleukin 6 (IL-6, −32.07 fold change), interleukin 7 receptor (IL-7R. −3.31 fold change), IL-8 (−8.17 fold change), IL-23, alpha subunit (IL23A, −5.46 fold change), and IL-1 beta (IL-1*β*, −2.28 fold change) genes, were downregulated by PC.

The genes downregulated by PC also included many Fc fragments of IgG receptors (FCGRs), leukocyte immunoglobulin-like receptors (LILRs), toll-like receptors (TLRs), and major histocompatibility complex (MHC) class II molecules genes, such as FCGR3B (−22.56 fold change), FCGR2B (−7.13 fold change), LILRB3 (−4.23 fold change), LILRB2 (−4.32 fold change), LILRB1 (−4.33 fold change), TLR8 (−5.55 fold change), TLR7 (−3.34 fold change), MHC class II, DP alpha 1 (HLA-DPA1, −2.83 fold change), MHC class II, DQ alpha 1 (HLA-DQA1, −3.39 fold), MHC class II, DR beta 1 (HLA-DRB1, −2.72 fold change), and MHC class II, DR beta 4 genes (HLA-DRB4, −2.81 fold change).

The expressions of many genes classified in inflammatory response and angiogenesis were also downregulated by PC. As shown in [Table 2](#tab2){ref-type="table"}, of the 73 differentially-expressed genes classified in inflammatory response, the expressions of 64 genes, including prostaglandin-endoperoxide synthase 2 (PTGS2/Cox-2, −34.01 fold change), S100 calcium binding protein A8 (S100A8, −16.53 fold change), complement factor D (CFD, −4.99 fold change), and allograft inflammatory factor 1 (AIF1, −2.76 fold change) genes, were downregulated by PC. Of the 51 differentially-expressed genes classified in angiogenesis, the expressions of 31 genes, including brain-specific angiogenesis inhibitor 3 (BAI3, −33.48 fold change), angiopoietin-like 4 (ANGPTL4, −11.43 fold change), and vascular endothelial growth factor A genes (VEGFA, −7.91 fold change), were downregulated by PC.

In contrast, the expressions of many genes classified in skeletal development, steroid biosynthetic process, and DNA repair were upregulated by PC. As shown in [Table 3](#tab3){ref-type="table"}, of the 26 differentially-expressed genes classified in skeletal development, the expressions of 17 genes, including collagen type II, alpha 1 (COL2A1, 21.29 fold change), collagen type XI, alpha 1 (COL11A1, 9.86 fold change), aggrecan (ACAN, 9.17 fold change), FGFR3 (2.40 fold change), FGF18 (2.33 fold change), and SOX-9 (2.00 fold change) genes, were upregulated by PC. Of the 16 differentially expressed genes classified in steroid biosynthetic process, the expressions of 11 genes, including squalene epoxidase (SQLE, 3.81 fold change) and steroid-5-alpha-reductase and alpha polypeptide 1 (SRD5A1, 3.75 fold change) genes, were upregulated by PC. Of the 7 differentially expressed genes classified in DNA repair, the expressions of 5 genes, including topoisomerase (DNA) II alpha 170 kDa (TOP2A, 3.75 fold change) and RAD52 homolog (RAD52B, 2.83 fold change) genes, were upregulated by PC.

We performed another independent microarray analysis using RNA samples extracted from meniscal explants derived from a different OA patient. Results from the two microarray analyses for select genes were listed in [Table 4](#tab4){ref-type="table"}. As shown, the results from the two microarray analyses were consistent. We also examined the expressions of selected genes using real-time quantitative RT-PCR. The results from the real-time RT-PCR for the genes examined were consistent with the results from the microarray analyses ([Table 4](#tab4){ref-type="table"}).

3.2. Immunohistochemical Staining {#sec3.2}
---------------------------------

To investigate whether PC-targeted genes were associated with OA, we decided to examine the expressions of selected PC-targeted genes in OA and normal menisci. Medial menisci derived from 6 end-stage OA patients and 3 osteosarcoma patients were used for the examinations. Representative images of the normal meniscus and OA menisci are shown in [Figure 1](#fig1){ref-type="fig"}.

The expressions of genes we selected for immunohistochemical examinations included FCGR3B, LILRB3, FGFR3 and SOX-9. FCGR3B and LILRB3 are two genes classified in the immune and inflammatory responses. FGFR3 and SOX-9 were two genes classified in the skeletal development. We first tested the antibodies specific to these proteins using human tissues known for their expression before using these antibodies to examine the meniscal tissues.

As shown in [Figure 2](#fig2){ref-type="fig"}, positive immunostainings were observed when these primary antibodies specific to these proteins were used whereas no immunostainings were observed when these primary antibodies were replaced by mouse IgG, confirming that these antibodies could be used to examine the expressions of FCGR3B, LILRB3, FGFR3, and SOX-9 in human tissues. We then used these antibodies to examine medial meniscal specimens derived from 6 end-stage OA patients (diseased tissues) and 3 osteosarcoma patients (control tissues). Representative images of FCGR3B immunostaining are provided in [Figure 2(a)](#fig2){ref-type="fig"}.

As shown, FCGR3B protein was detected in the surface zone of normal menisci. In contrast, FCGR3B was detected in both the surface and middle zones of OA menisci. It was clear that OA menisci contained more FCGR3B immunostaining-positive cells than the normal menisci, suggesting infiltration of inflammatory cells within the OA menisci. Representative images of LILRB3 immunostaining are provided in [Figure 3(b)](#fig3){ref-type="fig"}. As shown, LILRB3 protein was detected in all 3 zones (surface, middle, and deep zones) of the normal and OA menisci. OA menisci not only contained more LILRB3 immunostaining-positive cells but also displayed more intensified LILRB3 immunostaining compared to the normal menisci.

Representative images of FGFR3 and SOX-9 immunostaining are provided in [Figure 4](#fig4){ref-type="fig"}. As shown in [Figure 4(a)](#fig4){ref-type="fig"}, few FGFR3 immunostaining-positive cells were detected in the normal menisci and only a small number of FGFR3 immunostaining-positive cells were detected in the OA menisci. In contrast, strong SOX-9 immunostaining was detected in the normal menisci and the intensity of SOX-9 immunostaining and number of SOX-9 immunostaining-positive cells were decreased significantly in the OA menisci compared to the normal menisci ([Figure 4(b)](#fig4){ref-type="fig"}).

The immunostainings of FCGR3B, LILRB3, FGFR3, and SOX-9 were graded according to the scale described in Methods. The results along with the demographic patient information are listed in [Table 5](#tab5){ref-type="table"}. As shown, the mean grades of FCGR3B, LILRB3, FGFR3, and SOX-9 immunostainings for the normal menisci were 0.33, 1.33, 0.00, and 3.00, respectively, and the mean grades of FCGR3B, LILRB3, FGFR3, and SOX-9 immunostaining for the OA menisci were 2.00, 2.67, 1.17, and 1.50, respectively. The difference between the mean grades of FCGR3B, LILRB3, FGFR3, and SOX-9 immunostaining of the OA menisci and the normal menisci were statistically significant (*P* = 0.023, 0.010, 0.002, and 0.024, resp.).

4. Discussion {#sec4}
=============

There is increasing evidence indicating the involvement of immune system in OA. The expressions of several TLRs genes, which play a key role in innate immune system, were increased in OA cartilage and correlated with the severity of cartilage degeneration \[[@B24], [@B25]\]. The expressions of several MHC class II genes were increased in degenerative menisci of older patients and OA meniscal cells compared to younger patients and normal meniscal cells \[[@B4], [@B26]\]. In this study, we demonstrated that PC, which inhibited cartilage degeneration in Hartley guinea pigs \[[@B16]\], downregulated the expression of numerous genes classified in the immune response, including many TLRs genes ([Table 1](#tab1){ref-type="table"}, such as TLR-4 and TLR-8), MHC class II genes (such as HLA-DPA1, HLA-DRA, and HLA-DRB1), FCGRs genes (such as FCGR2B and FCGR3B), and LILRs genes (such as LILRA2, LILRB1, and LILRB3). These findings suggest that PC may be capable of reversing the abnormal expressions of many genes involved in immune system activation in OA menisci and cartilage.

Studies found that the expression of FCGRs, which help to bridge the adaptive and innate immune responses, and the expression of LILRs, which exert influence on signaling pathways of both innate and adaptive immune systems, were increased in inflammatory arthritis such as rheumatoid arthritis (RA) \[[@B27]--[@B30]\]. In addition, studies found that the numbers of FCGRs- and LILRs-positive immune cells were decreased in RA patients who responded to treatment with anti-rheumatic drugs \[[@B31], [@B32]\]. These previous findings indicate that abnormal expressions of FCGRs and LILRs are associated with inflammatory arthritis. In this study, we demonstrated that the expressions of FCGR3B and LILRB3 genes were increased in OA menisci and that their expressions in OA meniscal explant culture were inhibited by PC. These findings indicate that abnormal expressions of FCGRs and LILRs are also associated with OA. PC exerts its disease-modifying activity on OA, at least in part, by targeting abnormal immune system activation in OA.

Inflammation and angiogenesis are closely integrated processes in OA \[[@B33], [@B34]\]. A study demonstrated that inhibition of inflammation and angiogenesis reduced pain and retard joint damage in a rat model of OA \[[@B35]\]. In our study, we demonstrated that PC downregulated the expression of numerous genes classified in the inflammatory response and angiogenesis, including CCL5, CCR5, IL-8, IL-7R, IL-6, IL-1*β*, PTGS2/Cox-2, S100A8, ANGPTL4, and VEGFA. It is worth noting that abnormal expressions of these genes are associated with either OA or RA. For example, the protein levels of CCL5, IL-6, IL-8, IL-1*β*, S100A8, ANGPTL4, and VEGFA were increased in chondrocytes, cartilage, synovium, or synovial fluid derived from OA patients, which in turn stimulated the expression of MMPs \[[@B36]--[@B44]\]; the expression of IL-7R was elevated in RA FLSs and blockade of IL-7R reduced joint inflammation and cartilage destruction \[[@B45], [@B46]\]; PTGS2/Cox-2 is a key molecular target for the management of arthritis pain \[[@B47]\]. These findings together suggest that PC exerts its disease-modifying activity on OA, at least in part, by targeting abnormal inflammatory response and angiogenesis in OA. These findings also suggest that abnormal inflammatory response and angiogenesis in the menisci may be new target for OA intervention.

PC upregulated the expressions of many genes classified in skeletal development, including putative chondroprotective proteins FGFR3 and SOX-9 \[[@B48], [@B49]\]. To identify which proteins might be involved in the OA disease process, we examined the protein levels of FGFR3 and SOX-9 in normal and OA menisci. We found that FGFR3 protein was barely detected in the normal menisci and was slightly increased in OA menisci, suggesting that FGFR3 gene is unlikely a key OA disease candidate gene. In contrast, the protein level of SOX-9 was very high in the normal menisci but was significantly decreased in the OA menisci. This finding is consistent with the previous findings that the expression of SOX-9 gene was significantly decreased in OA articular cartilage and chondrocytes \[[@B50]--[@B52]\]. Taken together, it suggests that SOX-9 may be an OA disease candidate gene and that PC exerts its disease modifying activity on OA in part by reversing the abnormal expression of SOX-9 in OA menisci or cartilage. Study with SOX-9 knok-in or knock-out using an animal model of OA may provide more clues about the role of SOX-9 in OA.

A recent study reported that hundreds of genes were differentially expressed in degenerative menisci derived from older patients and younger patients \[[@B26]\]. The genes displayed higher expressions in the degenerative menisci derived from older patients compared to younger patients included HLA-DRB1 (15.01 fold change), FCER1A (4.15 fold change), and IL-7R (2.83 fold change) \[[@B26]\]. These findings are consistent with our findings and indicate that immune system activation occurs in the degenerative menisci. These findings, together with our findings, also suggest that increased expressions of HLA-DRB and IL-7R is likely a phenomenon associated with both the normal meniscal aging process and OA disease process whereas the increased expression of FCER1A is a phenomenon only associated with the normal meniscal aging process.

The genes displayed lower expression in the degenerative menisci derived from older patients included COL2A1 (−10.38 fold change) and FGFR3 (−4.65 fold change) \[[@B26]\]. These findings, together with our findings \[[@B23]\], indicate that the decreased expression of COL2A1 is likely a phenomenon associated with both the normal meniscal aging process and OA disease process whereas the decreased expression of FGFR3 is a phenomenon associated with the meniscal aging process. Our findings presented in this study demonstrate that PC affects the expressions of many genes involved in both OA disease process and meniscal aging process in the absence of calcium crystals. This suggests that PC is not only potentially a disease-modifying drug for calcification-induced OA therapy but also potentially a disease-modifying drug for noncalcification-induced arthritis therapy such as posttraumatic OA.

5. Conclusions {#sec5}
==============

OA is a disease associated with immune system activation and decreased expression of chondroprotective protein SOX-9. PC exerts its disease-modifying activity on OA, at least in part, by suppressing immune system activation and stimulating the production of extracellular cellular matrix proteins and chondroprotective proteins. PC is potentially a disease-modifying drug for noncalcification-induced arthritis therapy.
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![Images of normal and OA menisci. Meniscus derived from a male osteosarcoma patient, a male OA patient and a female OA patient. Menisci derived from OA patients exhibited discoloration and rough surface, with clear signs of degeneration whereas the normal control menisci had a smooth and glistening surface, with no signs of degeneration.](BMRI2014-210469.001){#fig1}

![(a) Positive FCGR3B immunostaining in human tonsil tissue, positive LILRB3 immunostaining in human tonsil tissue, positive FGFR3 immunostaining in human skin tissue, and positive SOX-9 immunostaining in human cartilage tissue. (b) Negative immunostaining of these proteins when primary antibodies were replaced by mouse IgG.](BMRI2014-210469.002){#fig2}

![Representative images of FCGR3B and LILR3B immunostaining (magnification 10x). (a) FCGR3B immunostaining of normal menisci and OA menisci. (b) LILRB3 immunostaining of normal menisci and OA menisci.](BMRI2014-210469.003){#fig3}

![Representative images of FGFR3 and SOX-9 immunostaining (magnification 10x). (a) FGFR3 immunostaining of normal menisci and OA menisci. (b) SOX-9 immunostaining of normal menisci and OA menisci.](BMRI2014-210469.004){#fig4}

###### 

Genes classified in the immune response.

  Biological process   Gene name   Gene ID     Differ expre^\*^   Description
  -------------------- ----------- ----------- ------------------ ----------------------------------------------------------------------
  Immune response                                                  
                       CCL20       NM_004591   −103.53            Chemokine (C-C motif) ligand 20
                       CCL5        NM_002985   −3.54              Chemokine (C-C motif) ligand 5
                       CCR5        NM_000579   −2.03              Chemokine (C-C motif) receptor 5
                       CXCL3       NM_002090   −10.03             Chemokine (C-X-C motif) ligand 3
                       CXCL5       AK026546    −4.49              Chemokine (C-X-C motif) ligand 5
                       CXCL2       M57731      −2.94              Chemokine (C-X-C motif) ligand 2
                       CXCL1       NM_001511   −3.01              Chemokine (C-X-C motif) ligand 1
                       CXCL9       NM_002416   −2.65              Chemokine (C-X-C motif) ligand 9
                       CXCL13      NM_006419   −2.62              Chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant)
                       CXCR4       AF348491    −2.63              Chemokine (C-X-C motif) receptor 4
                       IGKC        BC005332    −37.44             Netrin 2-like (chicken)
                       IL6         NM_000600   −32.07             Interleukin 6 (interferon, beta 2)
                       IL8         NM_000584   −8.17              Interleukin 8
                       IL23A       M15564      −7.89              Enhancer of polycomb homolog 1 (Drosophila)
                       IL24        NM_006850   −3.73              Interleukin 24
                       IL15        NM_000585   −3.70              Interleukin 15
                       IL7R        BE217880    −3.31              Interleukin 7 receptor
                       IL1B        NM_000576   −2.28              Interleukin 1, beta
                       IL1RN       BE563442    −2.80              Interleukin 1 receptor antagonist
                       MS4A2       NM_000139   −28.91             Membrane-spanning 4-domains, subfamily A, member 2
                       FCGR3B      NM_000570   −22.56             Fc fragment of IgG, low affinity IIIb, receptor (CD16b)
                       FCGR2B      U90940      −7.13              Fc fragment of IgG, low affinity IIc, receptor for (CD32)
                       FCGR1B      L03419      −3.30              Fc fragment of IgG, high affinity Ib, receptor (CD64)
                       FCER1A      BC005912    −5.19              Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide
                       HLA-C       AW575927    −22.41             Major histocompatibility complex, class I, C
                       HLA-F       BE138825    −2.22              Major histocompatibility complex, class I, F
                       AQP9        NM_020980   −17.49             Aquaporin 9
                       GZMA        NM_006144   −14.63             Granzyme A
                       IGHG1       M87789      −14.43             Immunoglobulin heavy constant gamma 1
                       LBP         M35533      −11.36             Lipopolysaccharide binding protein
                       EREG        NM_001432   −8.60              Epiregulin
                       CD86        NM_006889   −7.11              CD86 molecule
                       CD74        M28590      −2.76              CD74 molecule
                       CD40        NM_001250   −3.68              CD40 molecule, TNF receptor superfamily member 5
                       CD1D        NM_001766   −5.17              CD1d molecule
                       CD8A        AW006735    −4.99              CD8a molecule
                       CD14        NM_000591   −3.25              CD14 molecule
                       CD209       AF290886    −2.50              CD209 molecule
                       KYNU        BC000879    −6.69              Kynureninase (L-kynurenine hydrolase)
                       PTPRC       NM_002838   −5.88              Protein tyrosine phosphatase, receptor type, C
                       TLR8        AW872374    −5.55              Toll-like receptor 8
                       TLR7        NM_016562   −3.34              Toll-like receptor 7
                       TLR5        AF051151    −3.00              Toll-like receptor 5
                       TLR4        NM_003266   −2.40              Toll-like receptor 4
                       TLR2        NM_003264   −2.20              Toll-like receptor 2
                       TLR1        AL050262    −2.66              Toll-like receptor 1
                       SLC11A1     L32185      −5.41              Solute carrier family 11, member 1
                       CFD         NM_001928   −4.99              Complement factor D (adipsin)
                       CFI         BC020718    −3.37              Complement factor I
                       CFB         NM_001710   −2.39              Complement factor B
                       C3          NM_000064   −2.32              Complement component 3
                       CR1         AI052659    −2.24              Complement component (3b/4b) receptor 1 (Knops blood group)
                       C1QA        NM_015991   −2.20              Complement component 1, q subcomponent, A chain
                       C1QB        NM_000491   −2.10              Complement component 1, q subcomponent, B chain
                       C1RL        NM_016546   2.01               Complement component 1, r subcomponent-like
                       FYB         BF679849    −4.64              FYN binding protein (FYB-120/130)
                       TREM1       NM_018643   −4.52              Triggering receptor expressed on myeloid cells 1
                       BMP6        NM_001718   −4.48              Bone morphogenetic protein 6
                       INPP5D      U53470      −4.47              Inositol polyphosphate-5-phosphatase, 145 kDa
                       LILRB1      NM_006669   −4.33              Leukocyte immunoglobulin-like receptor, subfamily B, member 1
                       LILRB2      AF004231    −4.32              Leukocyte immunoglobulin-like receptor, subfamily B, member 2
                       LILRB3      AF009634    −4.23              leukocyte immunoglobulin-like receptor, subfamily B, member 3
                       LILRB4      U82979      −2.06              Leukocyte immunoglobulin-like receptor, subfamily B, member 4
                       LILRB5      NM_006840   −2.31              Leukocyte immunoglobulin-like receptor, subfamily B, member 5
                       LILRA2      NM_006866   −2.15              Leukocyte immunoglobulin-like receptor, subfamily A, member 2
                       ZEB1        NM_030751   −4.12              Zinc finger E-box binding homeobox 1
                       PLA2G7      M80436      −3.95              Platelet-activating factor receptor
                       MASP1       AI274095    −3.67              Mannan-binding lectin serine peptidase 1
                       EBI2        NM_004951   −3.59              Epstein-Barr virus induced gene 2
                       NOD2        NM_022162   −3.57              Nucleotide-binding oligomerization domain containing 2
                       LAIR1       NM_021708   −3.54              Leukocyte-associated immunoglobulin-like receptor 1
                       HLA-DQA1    BG397856    −3.38              Major histocompatibility complex, class II, DQ alpha 1
                       HLA-DQB1    M17955      −2.99              Major histocompatibility complex, class II, DQ beta 1
                       HLA-DRA     M60333      −3.22              Major histocompatibility complex, class II, DR alpha
                       HLA-DPA1    M27487      −2.83              Major histocompatibility complex, class II, DP alpha 1
                       HLA-DPB1    NM_002121   −2.15              Major histocompatibility complex, class II, DP beta 1
                       HLA-DRB4    BC005312    −2.81              Major histocompatibility complex, class II, DR beta 4
                       HLA-DRB1    AJ297586    −2.72              Major histocompatibility complex, class II, DR beta 3
                       HLA-DMB     NM_002118   −2.68              Major histocompatibility complex, class II, DM beta
                       HLA-DMA     X76775      −2.19              major histocompatibility complex, class II, DM alpha
                       LIF         NM_002309   −3.16              Leukemia inhibitory factor (cholinergic differentiation factor)
                       NCF4        NM_000631   −2.88              Neutrophil cytosolic factor 4, 40 kDa
                       PAG1        BF589359    −2.86              Phosphoprotein associated with glycosphingolipid microdomains 1
                       FYN         AK090692    −2.85              FYN oncogene related to SRC, FGR, YES
                       TREM2       NM_018965   −2.84              Triggering receptor expressed on myeloid cells 2
                       BST2        NM_004335   −2.84              Bone marrow stromal cell antigen 2
                       CTSG        NM_001911   −2.78              Cathepsin G
                       CTSS        AK024855    −2.60              Cathepsin S
                       MS4A1       AW474852    −2.74              Membrane-spanning 4-domains, subfamily A, member 1
                       NCF2        BC001606    −2.70              Neutrophil cytosolic factor 2
                       GPR65       NM_003608   −2.68              G protein-coupled receptor 65
                       GBP4        BG260886    −2.59              Guanylate binding protein 4
                       VAV1        NM_005428   −2.53              Vav 1 guanine nucleotide exchange factor
                       LCK         NM_005356   −2.49              Lymphocyte-specific protein tyrosine kinase
                       SYK         NM_003177   −2.42              Spleen tyrosine kinase
                       LY86        NM_004271   −2.36              Lymphocyte antigen 86
                       TNFSF10     U57059      −2.36              Tumor necrosis factor (ligand) superfamily, member 10
                       TNFSF13B    AF134715    −2.29              Tumor necrosis factor (ligand) superfamily, member 13b
                       IRF8        AI073984    −2.36              Interferon regulatory factor 8
                       RELB        NM_006509   −2.33              V-rel reticuloendotheliosis viral oncogene homolog B
                       SMAD6       AI628464    −2.25              SMAD family member 6
                       MBP         N37023      −2.24              Myelin basic protein
                       BCL6        S67779      −2.17              B-cell CLL/lymphoma 6 (zinc finger protein 51)
                       IGKC        BG485135    −2.12              Netrin 2-like (chicken)
                       CLEC7A      AF313468    −2.12              C-type lectin domain family 7, member A
                       LCP2        AI123251    −2.05              Lymphocyte cytosolic protein 2
                       IL31RA      AI123586    6.61               Interleukin 31 receptor A
                       C4BPA       NM_000715   3.34               Complement component 4 binding protein, alpha
                       ULBP2       AA831769    3.07               UL16 binding protein 2
                       CLEC4E      NM_014358   2.61               C-type lectin domain family 4, member E
                       TNFSF9      NM_003811   2.43               Tumor necrosis factor (ligand) superfamily, member 9
                       C7          NM_000587   2.36               Complement component 7
                       TGFB2       NM_003238   2.36               Transforming growth factor, beta 2
                       FAS         X83493      2.36               Fas (TNF receptor superfamily, member 6)
                       LAG3        NM_002286   2.26               Lymphocyte-activation gene 3
                       IL27RA      NM_004843   2.20               Interleukin 27 receptor, alpha
                       CD276       NM_025240   2.19               CD276 molecule
                       IL26        NM_018402   2.03               Interleukin 26
                       OAS1        NM_016816   2.02               2,5-oligoadenylate synthetase 1, 40/46 kDa

^\*^Negative number indicates decreased expression and positive number indicates increased expression (fold change) in PC-treated OA meniscal explants compared with untreated OA meniscal explants.

###### 

Genes classified in inflammatory response and angiogenesis.

  Biological process      Gene name   Gene ID     Differ expre (fold)^\*^   Description
  ----------------------- ----------- ----------- ------------------------- ----------------------------------------------------------------------
  Inflammatory response                                                      
                          CCL20       NM_004591   −103.53                   Chemokine (C-C motif) ligand 20
                          CCL5        NM_002985   −3.54                     Chemokine (C-C motif) ligand 5
                          CCR5        NM_000579   −2.03                     Chemokine (C-C motif) receptor 5
                          CXCL3       NM_002090   −10.03                    Chemokine (C-X-C motif) ligand 3
                          CXCL2       M57731      −2.94                     Chemokine (C-X-C motif) ligand 2
                          CXCL1       NM_001511   −3.01                     Chemokine (C-X-C motif) ligand 1
                          CXCL9       NM_002416   −2.65                     Chemokine (C-X-C motif) ligand 9
                          CXCL13      NM_006419   −2.62                     Chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant)
                          CXCR4       AF348491    −2.63                     Chemokine (C-X-C motif) receptor 4
                          PTGS2       AY151286    −34.01                    Prostaglandin-endoperoxide synthase 2
                          IL6         NM_000600   −32.07                    Interleukin 6 (interferon, beta 2)
                          IL23A       AF043179    −16.44                    Enhancer of polycomb homolog 1 (Drosophila)
                          IL8         NM_000584   −8.17                     Interleukin 8
                          IL1B        NM_000576   −2.28                     Interleukin 1, beta
                          IL1RN       BE563442    −2.80                     Interleukin 1 receptor antagonist
                          S100A8      NM_002964   −16.53                    S100 calcium binding protein A8
                          S100A9      NM_002965   −2.79                     S100 calcium binding protein A9
                          LBP         M35533      −11.36                    Lipopolysaccharide binding protein
                          APOE        NM_000041   −9.23                     Apolipoprotein E
                          FABP4       AI766029    −6.98                     Fatty acid binding protein 4, adipocyte
                          LYZ         U25677      −6.37                     Lysozyme (renal amyloidosis)
                          ITIH4       AI004137    −6.33                     Inter-alpha (globulin) inhibitor H4
                          BDKRB2      NM_000623   −6.01                     Bradykinin receptor B2
                          TLR8        AW872374    −5.55                     Toll-like receptor 8
                          TLR7        NM_016562   −3.34                     Toll-like receptor 7
                          TLR5        AF051151    −3.00                     Toll-like receptor 5
                          TLR4        NM_003266   −2.40                     Toll-like receptor 4
                          TLR2        NM_003264   −2.20                     Toll-like receptor 2
                          TLR1        AL050262    −2.66                     Toll-like receptor 1
                          AOX1        AB046692    −5.34                     Aldehyde oxidase 1
                          FCER1A      BC005912    −5.19                     Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide
                          CFD         NM_001928   −4.99                     Complement factor D (adipsin)
                          CFI         BC020718    −3.37                     Complement factor I
                          CFB         NM_001710   −2.39                     Complement factor B
                          C3          NM_000064   −2.32                     Complement component 3
                          CR1         AI052659    −2.24                     Complement component (3b/4b) receptor 1 (Knops blood group)
                          C1RL        NM_016546   −2.01                     Complement component 1, r subcomponent-like
                          C1QA        NM_015991   −2.20                     Complement component 1, q subcomponent, A chain
                          C1QB        NM_000491   −2.10                     Complement component 1, q subcomponent, B chain
                          AOAH        NM_001637   −4.89                     Acyloxyacyl hydrolase (neutrophil)
                          AGT         NM_000029   −4.66                     Angiotensinogen (serpin peptidase inhibitor, clade A, member 8)
                          BMP6        NM_001718   −4.48                     Bone morphogenetic protein 6
                          PLA2G7      M80436      −3.95                     Platelet-activating factor receptor
                          FOS         BC004490    −3.95                     V-fos FBJ murine osteosarcoma viral oncogene homolog
                          CD40        NM_001250   −3.68                     CD40 molecule, TNF receptor superfamily member 5
                          CD163       NM_004244   −3.68                     CD163 molecule
                          CD14        NM_000591   −3.25                     CD14 molecule
                          MASP1       AI274095    −3.67                     Mannan-binding lectin serine peptidase 1
                          F11R        AF191495    −3.16                     F11 receptor
                          ITGB2       L78790      −2.98                     Integrin, beta 2 (complement component 3 receptor 3 and 4 subunit)
                          NLRC4       NM_021209   −2.92                     NLR family, CARD domain containing 4
                          AIF1        U19713      −2.76                     Allograft inflammatory factor 1
                          ALOX5       NM_000698   −2.71                     Arachidonate 5-lipoxygenase
                          NOD1        AF126484    −2.66                     Nucleotide-binding oligomerization domain containing 1
                          JMJD3       AI830331    −2.46                     Jumonji domain containing 3, histone lysine demethylase
                          SIGLEC1     NM_023068   −2.46                     Sialic acid binding Ig-like lectin 1, sialoadhesin
                          TNFAIP6     AW188198    −2.37                     Tumor necrosis factor, alpha-induced protein 6
                          LY86        NM_004271   −2.36                     Lymphocyte antigen 86
                          AOC3        NM_003734   −2.31                     Amine oxidase, copper containing 3 (vascular adhesion protein 1)
                          TNFRSF1B    NM_001066   −2.21                     Tumor necrosis factor receptor superfamily, member 1B
                          BCL6        S67779      −2.17                     B-cell CLL/lymphoma 6 (zinc finger protein 51)
                          CLEC7A      AF313468    −2.12                     C-type lectin domain family 7, member A
                          CDO1        NM_001801   −2.11                     Cysteine dioxygenase, type I
                          NFATC4      AI806528    −2.04                     NF of activated T-cells, cytoplasmic, calcineurin-dependent 4
                          SERPINA3    NM_001085   5.20                      Serpin peptidase inhibitor, clade A, member 3
                          SERPINA1    AF119873    3.58                      Serpin peptidase inhibitor, clade A, member 1
                          C4BPA       NM_000715   3.34                      Complement component 4 binding protein, alpha
                          FN1         AJ276395    3.03                      Fibronectin 1
                          B4GALT1     D29805      2.99                      UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 1
                          GPR68       AI805006    2.40                      G protein-coupled receptor 68
                          C7          NM_000587   2.36                      Complement component 7
                          ANXA1       AU155094    2.23                      Annexin A1
                          KLKB1       NM_000892   2.21                      Cytochrome P450, family 4, subfamily V, polypeptide 2
  Angiogenesis                                                               
                          PTGS2       AY151286    −34.00                    Prostaglandin-endoperoxide synthase 2
                          BAI3        NM_001704   −33.48                    Brain-specific angiogenesis inhibitor 3
                          IL6         NM_000600   −32.08                    Interleukin 6 (interferon, beta 2)
                          IL8         NM_000584   −8.18                     Interleukin 8
                          IL1B        NM_000576   −2.28                     Interleukin 1, beta
                          SFRP1       AF017987    −17.55                    Secreted frizzled-related protein 1
                          ANGPTL4     AF169312    −11.43                    Angiopoietin-like 4
                          ANGPT2      BE501356    −2.56                     Angiopoietin 2
                          EREG        NM_001432   −8.60                     Epiregulin
                          VEGFA       M27281      −7.91                     Vascular endothelial growth factor A
                          VASH1       AU152507    −4.24                     Vasohibin 1
                          FLT1        U01134      −3.62                     Fms-related tyrosine kinase 1
                          PTPRB       AL080103    −3.48                     Protein tyrosine phosphatase, receptor type, B
                          FGF10       NM_004465   −3.34                     Fibroblast growth factor 10
                          LIF         NM_002309   −3.16                     Leukemia inhibitory factor (cholinergic differentiation factor)
                          BTG1        BC009050    −3.11                     B-cell translocation gene 1, anti-proliferative
                          DLL4        AB036931    −2.85                     Delta-like 4 (Drosophila)
                          SOX17       NM_022454   −2.45                     SRY (sex determining region Y)-box 17
                          EPAS1       NM_001430   −2.43                     Endothelial PAS domain protein 1
                          CTNNB1      AB062292    −2.35                     Catenin (cadherin-associated protein), beta 1, 88 kDa
                          TGFBR2      NM_003242   −2.35                     Transforming growth factor, beta receptor II (70/80 kDa)
                          TYMP        NM_001953   −2.34                     Thymidine phosphorylase
                          C3          NM_000064   −2.32                     Complement component 3
                          NRP1        AF280547    −2.19                     Neuropilin 1
                          NOTCH4      AI743713    −2.17                     Notch homolog 4 (Drosophila)
                          TSPAN12     AI056699    −2.16                     Tetraspanin 12
                          ADAM8       NM_001109   −2.15                     ADAM metallopeptidase domain 8
                          RHOB        AI263909    −2.12                     Ras homolog gene family, member B
                          HHEX        NM_001529   −2.12                     Hematopoietically expressed homeobox
                          THBS1       BF055462    −2.05                     Thrombospondin 1
                          KDR         NM_002253   −2.03                     Kinase insert domain receptor (a type III receptor tyrosine kinase)
                          GREM1       NM_013372   15.86                     Gremlin 1, cysteine knot superfamily, homolog (*Xenopus laevis*)
                          FGFR2       AB030078    4.49                      Fibroblast growth factor receptor 2
                          FGF1        X59065      2.39                      fibroblast growth factor 1 (acidic)
                          FGF18       AI798863    2.33                      Fibroblast growth factor 18
                          COL8A2      AI806793    4.46                      Collagen, type VIII, alpha 2
                          COL8A1      BE877796    3.30                      Collagen, type VIII, alpha 1
                          ARHGAP22    NM_021226   4.45                      Rho GTPase activating protein 22
                          TNFRSF12A   NM_016639   3.23                      Tumor necrosis factor receptor superfamily, member 12A
                          CSPG4       BE857703    3.14                      Chondroitin sulfate proteoglycan 4
                          WNT5B       NM_030775   3.10                      Wingless-type MMTV integration site family, member 5B
                          FN1         AJ276395    3.03                      Fibronectin 1
                          SFRP2       AF311912    3.00                      Secreted frizzled-related protein 2
                          B4GALT1     D29805      2.99                      UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 1
                          ANGPT1      NM_001146   2.62                      Angiopoietin 1
                          MFGE8       BC003610    2.39                      Milk fat globule-EGF factor 8 protein
                          TGFB2       NM_003238   2.36                      Transforming growth factor, beta 2
                          CYR61       NM_001554   2.30                      Cysteine-rich, angiogenic inducer, 61
                          MEOX2       NM_005924   2.15                      Mesenchyme homeobox 2
                          PLXDC1      NM_020405   2.09                      Plexin domain containing 1
                          TBXA2R      NM_001060   2.09                      Thromboxane A2 receptor

^\*^Negative number indicates decreased expression and positive number indicates increased expression (fold change).

###### 

Genes classified in skeletal development, steroid biosynthetic process, and DNA repair.

  Biological process             Gene name   Gene ID      Differ expre (fold)^\*^   Description
  ------------------------------ ----------- ------------ ------------------------- -----------------------------------------------------------------
  Skeletal development                                                               
                                 COL2A1      X06268       21.29                     Collagen, type II, alpha 1
                                 COL11A1     J04177       9.86                      Collagen, type XI, alpha 1
                                 COL1A1      AI743621     2.59                      Collagen, type I, alpha 1
                                 ACAN        NM_001135    9.17                      Aggrecan
                                 POSTN       AW137148     5.57                      Periostin, osteoblast specific factor
                                 PAX1        AA725078     4.73                      Paired box 1
                                 FRZB        U91903       3.22                      Frizzled-related protein
                                 MMP9        NM_004994    2.58                      Matrix metallopeptidase 9
                                 GLI2        NM_030379    2.54                      GLI-Kruppel family member GLI2
                                 FGFR3       NM_000142    2.40                      Fibroblast growth factor receptor 3
                                 FGF18       AI798863     2.33                      Fibroblast growth factor 18
                                 TGFB2       NM_003238    2.36                      Transforming growth factor, beta 2
                                 TRPS1       AK000948     2.32                      Trichorhinophalangeal syndrome I
                                 RUNX2       AW469546     2.24                      Runt-related transcription factor 2
                                 PRELP       U41344       2.15                      Proline/arginine-rich end leucine-rich repeat protein
                                 PAPSS2      AW299958     2.03                      3-phosphoadenosine 5-phosphosulfate synthase 2
                                 SOX9        NM_000346    2.00                      SRY (sex determining region Y)-box 9
                                 MEPE        NM_020203    −13.5                     Matrix, extracellular phosphoglycoprotein with ASARM motif
                                 PTHLH       BC005961     −6.79                     Parathyroid hormone-like hormone
                                 CHRDL2      AF332891     −6.20                     Chordin-like 2
                                 COL10A      X98568       −5.40                     collagen, type X, alpha 1 (Schmid metaphyseal chondrodysplasia)
                                 BMP6        NM_001718    −4.48                     Bone morphogenetic protein 6
                                 GDF10       NM_004962    −2.99                     Growth differentiation factor 10
                                 BMP8B       AA610122     −2.70                     Bone morphogenetic protein 8b
                                 TGFBR2      NM_003242    −2.35                     Transforming growth factor, beta receptor II (70/80 kDa)
                                 IGFBP4      NM_001552    −2.30                     Insulin-like growth factor binding protein 4
  Steroid biosynthetic process                                                       
                                 SQLE        AA639705     3.81                      Squalene epoxidase
                                 SRD5A1      NM_001047    3.75                      Steroid-5-alpha-reductase, alpha polypeptide 1
                                 FDXR        NM_004110    3.26                      Ferredoxin reductase
                                 HMGCS1      NM_002130    3.12                      3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble)
                                 HMGCR       AL518627     2.15                      3-hydroxy-3-methylglutaryl-Coenzyme A reductase
                                 LSS         D63807       3.04                      Lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase)
                                 DHCR24      NM_014762    2.66                      24-dehydrocholesterol reductase
                                 DHCR7       NM_001360    2.57                      7-dehydrocholesterol reductase
                                 OPRS1       NM_005866    2.62                      Opioid receptor, sigma 1
                                 CYB5R2      NM_016229    2.37                      Cytochrome b5 reductase 2
                                 SC5D        D85181       2.06                      Sterol-C5-desaturase
                                 BMP6        NM_001718    −4.48                     Bone morphogenetic protein 6
                                 CYP39A1     NM_016593    −2.21                     Cytochrome P450, family 39, subfamily A, polypeptide 1
                                 HSD3B7      BC004929     −2.10                     3 beta-hydroxysteroid dehydrogenase type 7
                                 ADM         NM_001124    −2.06                     Adrenomedullin
                                 ABCG1       NM_004915    −2.04                     ATP-binding cassette, sub-family G (WHITE), member 1
  DNA repair                                                                         
                                 TOP2A       AU159942     3.75                      Topoisomerase (DNA) II alpha 170 kDa
                                 RAD52B      AF125949     2.83                      RAD52 homolog (*S. cerevisiae*)
                                 RAD54B      NM_012415    2.05                      RAD54 homolog B (*S. cerevisiae*)
                                 TYMS        NM_001071    2.40                      Thymidylate synthetase
                                 RFC5        BG260658     2.39                      Replication factor C (activator 1) 5, 36.5 kDa
                                 SOD2        AL050388     −9.58                     Superoxide dismutase 2, mitochondrial
                                 REV3L       NM_002912    −3.08                     REV3-like, catalytic subunit of DNA polymerase zeta (yeast)

^\*^Negative number indicates decreased expression and positive number indicates increased expression (fold change).

###### 

Differential expression of selected genes.

  Gene name   Gene ID     Differential expression^\*^ microarray   Differential expression^\*\*^ microarray   Differential expression^\*\*\*^ real-time RT-PCR
  ----------- ----------- ---------------------------------------- ------------------------------------------ --------------------------------------------------
  CCL5        NM_002985   −3.54                                    −6.28                                      −3.69
  CCR5        NM_000579   −2.03                                    −2.95                                       
  FCGR3B      NM_000570   −6.49                                    −2.09                                       
  FCGR2B      M31933      −3.45                                    −3.72                                       
  IL6         NM_000600   −32.07                                   −1.85                                       
  IL7R        BE217880    −3.31                                    −11.0                                      −2.85
  IL8         NM_000584   −8.17                                    −2.25                                       
  IL23A       M15564      −7.89                                    −8.98                                       
  LILRB1      NM_006669   −4.33                                    −3.06                                       
  LILRB3      AF009634    −4.23                                    −3.38                                       
  TLR8        AW872374    −5.55                                    −3.55                                       
  TLR7        NM_016562   −3.34                                    −2.54                                       
  HLA-DRB1    AJ297586    −2.72                                    −3.41                                      −1.97
  S100A8      NM_002964   −16.53                                   −9.95                                       
  S100A9      NM_002965   −2.79                                    −4.70                                       
  PTPRC       NM_002838   −5.88                                    −2.85                                       
  SYK         NM_003177   −2.42                                    −2.99                                       
  BMP6        NM_001718   −4.48                                    −3.00                                       
  CPA3        NM_001870   −15.23                                   −9.37                                       
  CPM         BE878495    −3.17                                    −2.74                                       
  ADAMTS5     BI254089    −2.84                                    −1.98                                      −2.65
  ADAM28      NM_021778   −14.27                                   −3.59                                       
  MMP10       NM_002425   −2.41                                    −1.56                                       
  MMP1        NM_002421   −2.15                                    −1.83                                      −2.01
  FGFR3       NM_000142   2.40                                     1.52                                        
  SOX-9       NM_000346   2.00                                     1.70                                        
  POSTN       AW137148    5.57                                     2.76                                        
  COL2A1      X06268      21.29                                    1.76                                       3.11
  COL11A1     J04177      9.86                                     2.29                                        
  COL1A1      AI743621    2.59                                     1.79                                        
  ACAN        NM_001135   9.17                                     2.02                                       2.65

^\*^Negative number indicates decreased expression and positive number indicates increased expression (fold change).

^\*\*^Second microarray using different RNA samples extracted from meniscal explants derived from a different OA patient.

^\*\*\*^Results of real-time RC-PCR.

###### 

Grades of immunostaining of FCGR3B, LILRB3, FGFR3, and SOX-9.

  ------------------------------------------------------------------------------------------
                  Control\   Control\   Control\   OA\    OA\    OA\    OA\    OA\    OA\
                  12 F       43 M       39 F       77 M   49 F   66 F   70 F   57 M   65 F
  --------------- ---------- ---------- ---------- ------ ------ ------ ------ ------ ------
  FCGR3B          0          1          0          3      3      2      2      1      1

  Mean (FCGR3B)   **0.33**   **2.00**                                                 

                                                                                      

  LILRB3          1          2          1          2      3      3      2      3      3

  Mean (LILRB3)   **1.33**   **2.67**                                                 

                                                                                      

  FGFR3           0          0          0          1      1      1      1      2      1

  Mean (FGFR3)    **0.00**   **1.17**                                                 

                                                                                      

  SOX-9           3          3          3          2      1      1      1      2      2

  Mean (SOX-9)    **3.00**   **1.50**                                                 
  ------------------------------------------------------------------------------------------

Ages of the patients are listed in years; M = male; F = female.

[^1]: Academic Editor: Hiroshi Tanaka
